Costa Carlos 4
4 · Foghorn Therapeutics Inc. · Filed Sep 24, 2024
Insider Transaction Report
Form 4
Costa Carlos
Chief People Officer
Transactions
- Sale
Common Stock
2024-09-23$10.17/sh−857$8,716→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-20−35,756→ 40,646 totalExercise: $3.72Exp: 2029-02-12→ Common Stock (35,756 underlying) - Exercise/Conversion
Common Stock
2024-09-23$3.72/sh+857$3,188→ 857 total - Exercise/Conversion
Common Stock
2024-09-20$3.72/sh+35,756$133,012→ 35,756 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-23−857→ 39,789 totalExercise: $3.72Exp: 2029-02-12→ Common Stock (857 underlying) - Sale
Common Stock
2024-09-20$10.04/sh−35,756$358,990→ 0 total
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.22 per share.
- [F3]The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested.